deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01432574

Study of Gardasil in Mid-Adult Males (MAM)

A Phase II Study of Gardasil in Human Papillomavirus Research The Mid-Adult Male Vaccine Study - The MAM STUDY

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Conditions Human Papillomavirus
Interventions Gardasil
Updated 20 times since 2017 Last updated: Sep 13, 2021 Started: Feb 19, 2013 Primary completion: May 23, 2014 Completion: Nov 3, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01432574, this PHASE2 trial focuses on Human Papillomavirus and remains completed. Sponsored by H. Lee Moffitt Cancer Center and Research Institute, it has been updated 20 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Sep 2017 · 4 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Mar 2019 · 5 months · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Jan 2020 · 5 months · monthly snapshot~Jan 2020 – ~Jun 2020 · 5 months · monthly snapshot~Jun 2020 – ~Nov 2020 · 5 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2021 — Jun 2022 [monthly]

    Completed PHASE2

  5. Oct 2021 — Dec 2021 [monthly]

    Completed PHASE2

▶ Show 15 earlier versions

  1. Sep 2021 — Oct 2021 [monthly]

    Completed PHASE2

  2. Apr 2021 — Sep 2021 [monthly]

    Completed PHASE2

  3. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE2

  4. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  8. Aug 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE2

  9. Mar 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  10. Oct 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  11. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

  12. Sep 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  13. May 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

  14. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

  15. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • H. Lee Moffitt Cancer Center and Research Institute
  • Merck Sharp & Dohme LLC
Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations